Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| BCLS Acquisition Corp.BLSA · Entity 145747 | Director | October 22, 2020 | October 22, 2020 |
| Kalaris Therapeutics, Inc.ALVR · Entity 6805 | Director · See Remarks · 10% owner | February 21, 2025 | February 24, 2025 |
| Scholar Rock Holding CorpSRRK · Entity 3721 | Chief Financial Officer | April 16, 2026 | April 20, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
BCLS Acquisition Corp.
Report date October 22, 2020 · Filed October 22, 2020
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Class B ordinary sharesSEC Table II · derivative / convertible security | Direct | Not disclosed |
Reported balance
Holding disclosure · report date 2020-10-22 · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · Balance Not disclosed F1: As described in the issuer's registration statement on Form S-1 (File No. 333-249284) under the heading "Description of Securities--Founder Shares", the shares of Class B ordinary shares, par value $0.0001 per share, will automatically convert into shares of Class A ordinary shares, par value $0.0001 per share, of the issuer at the time of the issuer's initial business combination on a one-for-one basis, subject to adjustment for stock splits, stock dividends, reorganizations, recapitalizations and the like, and certain anti-dilution rights and have no expiration date. |
Filing footnotes · ownership attribution and instrument terms
F1: As described in the issuer's registration statement on Form S-1 (File No. 333-249284) under the heading "Description of Securities--Founder Shares", the shares of Class B ordinary shares, par value $0.0001 per share, will automatically convert into shares of Class A ordinary shares, par value $0.0001 per share, of the issuer at the time of the issuer's initial business combination on a one-for-one basis, subject to adjustment for stock splits, stock dividends, reorganizations, recapitalizations and the like, and certain anti-dilution rights and have no expiration date.
Kalaris Therapeutics, Inc.
Report date February 21, 2025 · Filed February 24, 2025
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 49,129 |
Reported balance
After 2025-02-21 transaction · row 1
1 source rowRow 1 · 2025-02-21 · Sale · Disposed 303 · Balance 49,129 F1: Represents shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units. These sales were automatic and not in the discretion of the Reporting Person. F2: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $10.06 to $10.13. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request. |
| Common StockSEC Table I · non-derivative | IndirectSee footnote | 724,989 |
Reported balance
Holding disclosure · report date 2025-02-21 · row 2
Holding and transaction disclosures are not merged.
1 source rowRow 2 · Balance 724,989 F3: Shares held by ElevateBio. The Reporting Person is a director and Chief Financial Officer of ElevateBio, and may be deemed to have shared voting and investment power of the shares held by ElevateBio. The Reporting Person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units. These sales were automatic and not in the discretion of the Reporting Person.
F2: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $10.06 to $10.13. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request.
F3: Shares held by ElevateBio. The Reporting Person is a director and Chief Financial Officer of ElevateBio, and may be deemed to have shared voting and investment power of the shares held by ElevateBio. The Reporting Person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose.
Scholar Rock Holding Corp
Report date April 16, 2026 · Filed April 20, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 619,856 |
Reported balance
After 2026-04-16 transaction · row 1
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 1 · 2026-04-16 · Sale · Disposed 10,410 · Balance 619,856 F1: Represents the number of shares required to be sold by the reporting person to cover the tax withholding obligation in connection with the vesting of restricted stock units ("RSUs") on April 15, 2026. This sale is mandated by the Issuer's election under its equity incentive plans to require the reporting person to fund this tax withholding obligation by completing a "sell to cover" transaction with a brokerage firm designated by the Issuer. This sale does not represent a discretionary trade by the reporting person. The shares vested pursuant to awards that were granted on April 27, 2025. Each RSU represents the contingent right to receive upon vesting of the RSU, one share of the Issuer's common stock. The shares subject to these RSU awards vest annually over four years, subject to a continued service relationship with the Issuer on the applicable vesting date. F2: Consists of 47,835 shares of common stock, 122,021 RSUs subject to time-based vesting conditions and 450,000 RSUs subject to performance- and time-based vesting conditions. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents the number of shares required to be sold by the reporting person to cover the tax withholding obligation in connection with the vesting of restricted stock units ("RSUs") on April 15, 2026. This sale is mandated by the Issuer's election under its equity incentive plans to require the reporting person to fund this tax withholding obligation by completing a "sell to cover" transaction with a brokerage firm designated by the Issuer. This sale does not represent a discretionary trade by the reporting person. The shares vested pursuant to awards that were granted on April 27, 2025. Each RSU represents the contingent right to receive upon vesting of the RSU, one share of the Issuer's common stock. The shares subject to these RSU awards vest annually over four years, subject to a continued service relationship with the Issuer on the applicable vesting date.
F2: Consists of 47,835 shares of common stock, 122,021 RSUs subject to time-based vesting conditions and 450,000 RSUs subject to performance- and time-based vesting conditions.
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
Verona Pharma plc
Report date October 07, 2025 · Filed October 08, 2025
Section 16 reporting ended · disclosed 2025-10-08. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Ordinary SharesSEC Table I · non-derivative | Direct | 0 |
Last balance in matching sequence
After 2025-10-07 transaction · row 3
Source-order balances reconcile. Account continuity and personal attribution are not independently verified.
3 source rowsRow 1 · 2025-10-07 · Disposition to issuer · Disposed 94,112 · Balance 0 F1: Reported securities are represented by American Depositary Shares ("ADSs"), each of which represents eight (8) Ordinary Shares of the Issuer. F2: Represents Ordinary Shares of the Issuer acquired from the Reporting Person by means of a scheme of arrangement (the "Scheme of Arrangement") under Part 26 of the UK Companies Act 2006, pursuant to a transaction agreement, dated as of July 8, 2025 (the "Transaction Agreement"), by and among the Issuer, Merck Sharp & Dohme LLC, a New Jersey limited liability company ("Parent") and Vol Holdings LLC, a Delaware limited liability company and wholly owned subsidiary of Parent ("Bidco"). F3: At the effective time of the Scheme of Arrangement (the "Effective Time"), each holder of the Scheme Shares (as defined in the Scheme of Arrangement) became entitled to receive $13.375 in cash per Scheme Share, without interest and net of any applicable withholding taxes. Because each ADS represents a beneficial ownership interest in eight (8) Ordinary Shares of the Issuer, holders of ADSs as of the Effective Time became entitled to receive eight (8) times the foregoing cash amount, or $107 in cash, without interest and net of any applicable withholding taxes, per ADS (the "ADS Consideration"). Row 2 · 2025-10-07 · Exercise / conversion · Acquired 72,000 · Balance 72,000 F1: Reported securities are represented by American Depositary Shares ("ADSs"), each of which represents eight (8) Ordinary Shares of the Issuer. F4: Pursuant to the terms of the Transaction Agreement, immediately prior to the Effective Time, each outstanding time-based restricted share unit award ("RSU Award"), unless agreed otherwise, became fully vested, and at the Effective Time, was automatically converted into the right to receive an amount in cash (without interest and subject to all required withholding taxes) equal to the product of (i) the aggregate number of ADSs underlying such RSU Award and (ii) the ADS Consideration. Row 3 · 2025-10-07 · Disposition to issuer · Disposed 72,000 · Balance 0 F1: Reported securities are represented by American Depositary Shares ("ADSs"), each of which represents eight (8) Ordinary Shares of the Issuer. F4: Pursuant to the terms of the Transaction Agreement, immediately prior to the Effective Time, each outstanding time-based restricted share unit award ("RSU Award"), unless agreed otherwise, became fully vested, and at the Effective Time, was automatically converted into the right to receive an amount in cash (without interest and subject to all required withholding taxes) equal to the product of (i) the aggregate number of ADSs underlying such RSU Award and (ii) the ADS Consideration. |
| Restricted Share UnitSEC Table II · derivative / convertible security | Direct | 0 |
Reported balance
After 2025-10-07 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2025-10-07 · Exercise / conversion · Disposed 72,000 · Balance 0 F5: Represents an award of RSUs covering ADSs, which is presented in terms of the equivalent number of Ordinary Shares underlying the ADSs. Each RSU represents a contingent right to receive one (1) ADS of the Issuer. Each ADS represents eight (8) Ordinary Shares of the Issuer. The RSUs have no expiration date. F4: Pursuant to the terms of the Transaction Agreement, immediately prior to the Effective Time, each outstanding time-based restricted share unit award ("RSU Award"), unless agreed otherwise, became fully vested, and at the Effective Time, was automatically converted into the right to receive an amount in cash (without interest and subject to all required withholding taxes) equal to the product of (i) the aggregate number of ADSs underlying such RSU Award and (ii) the ADS Consideration. F1: Reported securities are represented by American Depositary Shares ("ADSs"), each of which represents eight (8) Ordinary Shares of the Issuer. |
| Share Options (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $0.50 · Expires 2032-04-27 | Direct | 0 |
Reported balance
After 2025-10-07 transaction · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · 2025-10-07 · Disposition to issuer · Disposed 384 · Balance 0 F6: Pursuant to the terms of the Transaction Agreement, immediately prior to the Effective Time, each outstanding share option became fully vested, to the extent unvested, and at the Effective Time, each share option that had an exercise price less than the ADS Consideration was automatically converted into the right to receive an amount in cash equal to the product of (i) the aggregate number of ADSs underlying such share option and (ii) the excess, if any, of (a) an amount equal to the ADS Consideration over (b) the exercise price of such share option. F1: Reported securities are represented by American Depositary Shares ("ADSs"), each of which represents eight (8) Ordinary Shares of the Issuer. |
| Share Options (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $2.67 · Expires 2033-04-27 | Direct | 0 |
Reported balance
After 2025-10-07 transaction · row 6
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 6 · 2025-10-07 · Disposition to issuer · Disposed 96,000 · Balance 0 F6: Pursuant to the terms of the Transaction Agreement, immediately prior to the Effective Time, each outstanding share option became fully vested, to the extent unvested, and at the Effective Time, each share option that had an exercise price less than the ADS Consideration was automatically converted into the right to receive an amount in cash equal to the product of (i) the aggregate number of ADSs underlying such share option and (ii) the excess, if any, of (a) an amount equal to the ADS Consideration over (b) the exercise price of such share option. F1: Reported securities are represented by American Depositary Shares ("ADSs"), each of which represents eight (8) Ordinary Shares of the Issuer. |
| Share Options (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.93 · Expires 2034-04-28 | Direct | 0 |
Reported balance
After 2025-10-07 transaction · row 7
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 7 · 2025-10-07 · Disposition to issuer · Disposed 240,000 · Balance 0 F6: Pursuant to the terms of the Transaction Agreement, immediately prior to the Effective Time, each outstanding share option became fully vested, to the extent unvested, and at the Effective Time, each share option that had an exercise price less than the ADS Consideration was automatically converted into the right to receive an amount in cash equal to the product of (i) the aggregate number of ADSs underlying such share option and (ii) the excess, if any, of (a) an amount equal to the ADS Consideration over (b) the exercise price of such share option. F1: Reported securities are represented by American Depositary Shares ("ADSs"), each of which represents eight (8) Ordinary Shares of the Issuer. |
| Share Options (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $0.78 · Expires 2031-08-08 | Direct | 0 |
Reported balance
After 2025-10-07 transaction · row 8
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 8 · 2025-10-07 · Disposition to issuer · Disposed 64,000 · Balance 0 F6: Pursuant to the terms of the Transaction Agreement, immediately prior to the Effective Time, each outstanding share option became fully vested, to the extent unvested, and at the Effective Time, each share option that had an exercise price less than the ADS Consideration was automatically converted into the right to receive an amount in cash equal to the product of (i) the aggregate number of ADSs underlying such share option and (ii) the excess, if any, of (a) an amount equal to the ADS Consideration over (b) the exercise price of such share option. F1: Reported securities are represented by American Depositary Shares ("ADSs"), each of which represents eight (8) Ordinary Shares of the Issuer. |
Filing footnotes · ownership attribution and instrument terms
F1: Reported securities are represented by American Depositary Shares ("ADSs"), each of which represents eight (8) Ordinary Shares of the Issuer.
F2: Represents Ordinary Shares of the Issuer acquired from the Reporting Person by means of a scheme of arrangement (the "Scheme of Arrangement") under Part 26 of the UK Companies Act 2006, pursuant to a transaction agreement, dated as of July 8, 2025 (the "Transaction Agreement"), by and among the Issuer, Merck Sharp & Dohme LLC, a New Jersey limited liability company ("Parent") and Vol Holdings LLC, a Delaware limited liability company and wholly owned subsidiary of Parent ("Bidco").
F3: At the effective time of the Scheme of Arrangement (the "Effective Time"), each holder of the Scheme Shares (as defined in the Scheme of Arrangement) became entitled to receive $13.375 in cash per Scheme Share, without interest and net of any applicable withholding taxes. Because each ADS represents a beneficial ownership interest in eight (8) Ordinary Shares of the Issuer, holders of ADSs as of the Effective Time became entitled to receive eight (8) times the foregoing cash amount, or $107 in cash, without interest and net of any applicable withholding taxes, per ADS (the "ADS Consideration").
F4: Pursuant to the terms of the Transaction Agreement, immediately prior to the Effective Time, each outstanding time-based restricted share unit award ("RSU Award"), unless agreed otherwise, became fully vested, and at the Effective Time, was automatically converted into the right to receive an amount in cash (without interest and subject to all required withholding taxes) equal to the product of (i) the aggregate number of ADSs underlying such RSU Award and (ii) the ADS Consideration.
F5: Represents an award of RSUs covering ADSs, which is presented in terms of the equivalent number of Ordinary Shares underlying the ADSs. Each RSU represents a contingent right to receive one (1) ADS of the Issuer. Each ADS represents eight (8) Ordinary Shares of the Issuer. The RSUs have no expiration date.
F6: Pursuant to the terms of the Transaction Agreement, immediately prior to the Effective Time, each outstanding share option became fully vested, to the extent unvested, and at the Effective Time, each share option that had an exercise price less than the ADS Consideration was automatically converted into the right to receive an amount in cash equal to the product of (i) the aggregate number of ADSs underlying such share option and (ii) the excess, if any, of (a) an amount equal to the ADS Consideration over (b) the exercise price of such share option.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| April 22, 2024 Filed Apr 23, 2024 20:15 UTC | Kalaris Therapeutics, Inc. ALVR · Entity 6805 | SaleCommon Stock | 1,857 | $0.75 | $1,392.75 |
DisclosureSEC source: 0000950170-24-046905 · ownership.xml · nonDerivative · entry 2 Sinha Vikas · CIK 0001337845 · Director · See Remarks · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,138,096 F1 · kind: Represents shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units. These sales were automatic and not in the discretion of the Reporting Person. Read SEC document |
| April 19, 2024 Filed Apr 23, 2024 20:15 UTC | Kalaris Therapeutics, Inc. ALVR · Entity 6805 | SaleCommon Stock | 1,521 | $0.75 | $1,141.66 |
DisclosureSEC source: 0000950170-24-046905 · ownership.xml · nonDerivative · entry 1 Sinha Vikas · CIK 0001337845 · Director · See Remarks · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,139,953 F1 · kind: Represents shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units. These sales were automatic and not in the discretion of the Reporting Person. F2 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $0.7460 to $0.7562. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request. Read SEC document |
| April 02, 2024 Filed Apr 4, 2024 20:15 UTC | Kalaris Therapeutics, Inc. ALVR · Entity 6805 | SaleCommon Stock | 885 | $0.77 | $683.22 |
DisclosureSEC source: 0000950170-24-041808 · ownership.xml · nonDerivative · entry 1 Sinha Vikas · CIK 0001337845 · Director · See Remarks · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,141,474 F1 · kind: Represents shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units. These sales were automatic and not in the discretion of the Reporting Person. F2 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $0.7513 to $0.7801. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request. Read SEC document |
| February 20, 2024 Filed Feb 22, 2024 21:15 UTC | Kalaris Therapeutics, Inc. ALVR · Entity 6805 | SaleCommon Stock | 2,893 | $0.70 | $2,011.21 |
DisclosureSEC source: 0000950170-24-018783 · ownership.xml · nonDerivative · entry 1 Sinha Vikas · CIK 0001337845 · Director · See Remarks · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,142,359 F1 · kind: Represents shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units. These sales were automatic and not in the discretion of the Reporting Person. F2 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $0.6832 to $0.7150. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request. Read SEC document |
| February 05, 2024 Filed Feb 6, 2024 21:46 UTC | Kalaris Therapeutics, Inc. ALVR · Entity 6805 | SaleCommon Stock | 18,331 | $0.67 | $12,281.77 |
DisclosureSEC source: 0000950170-24-011778 · ownership.xml · nonDerivative · entry 1 Sinha Vikas · CIK 0001337845 · Director · See Remarks · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,145,252 F1 · kind: Represents shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units. These sales were automatic and not in the discretion of the Reporting Person. F2 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $0.66 to $0.6914. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request. Read SEC document |
| January 23, 2024 Filed Jan 25, 2024 21:15 UTC | Kalaris Therapeutics, Inc. ALVR · Entity 6805 | SaleCommon Stock | 3,205 | $0.67 | $2,149.91 |
DisclosureSEC source: 0000950170-24-007407 · ownership.xml · nonDerivative · entry 1 Sinha Vikas · CIK 0001337845 · Director · See Remarks · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,163,583 F1 · kind: Represents shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units. These sales were automatic and not in the discretion of the Reporting Person. F2 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $0.6683 to $0.6797. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request. Read SEC document |
| January 04, 2024 Filed Jan 8, 2024 21:15 UTC | Kalaris Therapeutics, Inc. ALVR · Entity 6805 | SaleCommon Stock | 961 | $0.64 | $614.08 |
DisclosureSEC source: 0000950170-24-002938 · ownership.xml · nonDerivative · entry 1 Sinha Vikas · CIK 0001337845 · Director · See Remarks · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,166,788 F1 · kind: Represents shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units. These sales were automatic and not in the discretion of the Reporting Person. Read SEC document |
| November 17, 2023 Filed Nov 21, 2023 22:00 UTC | Kalaris Therapeutics, Inc. ALVR · Entity 6805 | SaleCommon Stock | 2,490 | $1.63 | $4,061.44 |
DisclosureSEC source: 0001209191-23-056316 · doc4.xml · nonDerivative · entry 1 Sinha Vikas · CIK 0001337845 · Director · See Remarks · 10% owner 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 1,167,749 F1 · kind: Represents shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units. These sales were automatic and not in the discretion of the Reporting Person. F2 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $1.61 to $1.67. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request. Read SEC document |
| October 20, 2023 Filed Oct 23, 2023 21:00 UTC | Kalaris Therapeutics, Inc. ALVR · Entity 6805 | SaleCommon Stock | 1,475 | $1.54 | $2,272.98 |
DisclosureSEC source: 0001209191-23-053348 · doc4.xml · nonDerivative · entry 2 Sinha Vikas · CIK 0001337845 · Director · See Remarks · 10% owner 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 1,170,239 F1 · kind: Represents shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units. These sales were automatic and not in the discretion of the Reporting Person. F2 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $1.53 to $1.56. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request. Read SEC document |
| October 19, 2023 Filed Oct 23, 2023 21:00 UTC | Kalaris Therapeutics, Inc. ALVR · Entity 6805 | SaleCommon Stock | 1,232 | $1.58 | $1,946.56 |
DisclosureSEC source: 0001209191-23-053348 · doc4.xml · nonDerivative · entry 1 Sinha Vikas · CIK 0001337845 · Director · See Remarks · 10% owner 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 1,171,714 F1 · kind: Represents shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units. These sales were automatic and not in the discretion of the Reporting Person. Read SEC document |
| October 03, 2023 Filed Oct 5, 2023 21:00 UTC | Kalaris Therapeutics, Inc. ALVR · Entity 6805 | SaleCommon Stock | 755 | $1.98 | $1,492.11 |
DisclosureSEC source: 0001209191-23-052228 · doc4.xml · nonDerivative · entry 1 Sinha Vikas · CIK 0001337845 · Director · See Remarks · 10% owner 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 1,172,946 F1 · kind: Represents shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units. These sales were automatic and not in the discretion of the Reporting Person. F2 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $1.95 to $2.03. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request. Read SEC document |
| August 17, 2023 Filed Aug 21, 2023 21:00 UTC | Kalaris Therapeutics, Inc. ALVR · Entity 6805 | SaleCommon Stock | 10,516 | $2.50 | $26,242.68 |
DisclosureSEC source: 0001209191-23-046735 · doc4.xml · nonDerivative · entry 1 Sinha Vikas · CIK 0001337845 · Director · See Remarks · 10% owner 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 1,173,701 F1 · kind: Represents shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units. These sales were automatic and not in the discretion of the Reporting Person. F2 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $2.45 to $2.56. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request. Read SEC document |
| July 20, 2023 Filed Jul 21, 2023 21:00 UTC | Kalaris Therapeutics, Inc. ALVR · Entity 6805 | SaleCommon Stock | 1,437 | $3.35 | $4,810.21 |
DisclosureSEC source: 0001209191-23-043119 · doc4.xml · nonDerivative · entry 2 Sinha Vikas · CIK 0001337845 · Director · See Remarks · 10% owner 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 1,184,217 F1 · kind: Represents shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units. These sales were automatic and not in the discretion of the Reporting Person. F3 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $3.26 to $3.47. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request. Read SEC document |
| July 19, 2023 Filed Jul 21, 2023 21:00 UTC | Kalaris Therapeutics, Inc. ALVR · Entity 6805 | SaleCommon Stock | 1,198 | $3.56 | $4,266.68 |
DisclosureSEC source: 0001209191-23-043119 · doc4.xml · nonDerivative · entry 1 Sinha Vikas · CIK 0001337845 · Director · See Remarks · 10% owner 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 1,185,654 F1 · kind: Represents shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units. These sales were automatic and not in the discretion of the Reporting Person. F2 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $3.53 to $3.62. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request. Read SEC document |
| July 05, 2023 Filed Jul 6, 2023 21:00 UTC | Kalaris Therapeutics, Inc. ALVR · Entity 6805 | SaleCommon Stock | 2,983 | $3.05 | $9,083.53 |
DisclosureSEC source: 0001209191-23-041582 · doc4.xml · nonDerivative · entry 1 Sinha Vikas · CIK 0001337845 · Director · See Remarks · 10% owner 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 1,186,852 F1 · kind: Represents shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units. These sales were automatic and not in the discretion of the Reporting Person. F2 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $2.96 to $3.15. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request. F3 · balance_after: Includes 4,780 shares acquired under the AlloVir, Inc. 2020 Employee Stock Purchase Plan on June 30, 2023. Read SEC document |
| April 28, 2023 Filed Apr 28, 2023 20:18 UTC | Verona Pharma plc VRNA · Entity 74409 | GrantShare Options (Right to Buy) · Derivative | 96,000 | $0.00 Strike: $2.67 | $0.00 |
DisclosureSEC source: 0001104659-23-052996 · tm2314094-4_4seq1.xml · derivative · entry 1 Sinha Vikas · CIK 0001337845 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 96,000 Underlying: Ordinary Shares · 96,000 shares Expires 2033-04-27 F1 · derivative.exercise_price: The number of securities underlying the option and the exercise price therefor are listed in terms of Ordinary Shares, however, each security is represented by American Depositary Shares ("ADSs"), each of which represents eight (8) Ordinary Shares of the Issuer. F1 · shares: The number of securities underlying the option and the exercise price therefor are listed in terms of Ordinary Shares, however, each security is represented by American Depositary Shares ("ADSs"), each of which represents eight (8) Ordinary Shares of the Issuer. F2 · derivative.exercise_date: The option vests and becomes exercisable as to 25% on each of July 28, 2023, October 28, 2023, January 28, 2024 and April 28, 2024. F1 · derivative.underlying_shares: The number of securities underlying the option and the exercise price therefor are listed in terms of Ordinary Shares, however, each security is represented by American Depositary Shares ("ADSs"), each of which represents eight (8) Ordinary Shares of the Issuer. F1 · balance_after: The number of securities underlying the option and the exercise price therefor are listed in terms of Ordinary Shares, however, each security is represented by American Depositary Shares ("ADSs"), each of which represents eight (8) Ordinary Shares of the Issuer. Read SEC document |
| April 20, 2023 Filed Apr 21, 2023 20:05 UTC | Kalaris Therapeutics, Inc. ALVR · Entity 6805 | SaleCommon Stock | 1,466 | $3.63 | $5,314.98 |
DisclosureSEC source: 0001209191-23-025128 · doc4.xml · nonDerivative · entry 2 Sinha Vikas · CIK 0001337845 · Director · See Remarks · 10% owner 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 1,185,055 F1 · kind: Represents shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units. These sales were automatic and not in the discretion of the Reporting Person. F3 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $3.62 to $3.64. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request. Read SEC document |
| April 19, 2023 Filed Apr 21, 2023 20:05 UTC | Kalaris Therapeutics, Inc. ALVR · Entity 6805 | SaleCommon Stock | 1,217 | $3.71 | $4,513.49 |
DisclosureSEC source: 0001209191-23-025128 · doc4.xml · nonDerivative · entry 1 Sinha Vikas · CIK 0001337845 · Director · See Remarks · 10% owner 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 1,186,521 F1 · kind: Represents shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units. These sales were automatic and not in the discretion of the Reporting Person. F2 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $3.64 to $3.84. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request. Read SEC document |
| February 02, 2023 Filed Feb 3, 2023 22:00 UTC | Kalaris Therapeutics, Inc. ALVR · Entity 6805 | GrantStock Option (Right to Buy) · Derivative | 292,500 | $0.00 Strike: $6.65 | $0.00 |
DisclosureSEC source: 0001209191-23-006995 · doc4.xml · derivative · entry 3 Sinha Vikas · CIK 0001337845 · Director · See Remarks · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,012,362 Underlying: Common Stock · 292,500 shares Expires 2033-02-02 F3 · derivative.exercise_date: 25% of this option shall vest and become exercisable on February 2, 2024, with the remainder vesting in twelve equal quarterly installments thereafter. Read SEC document |
| February 02, 2023 Filed Feb 3, 2023 22:00 UTC | Kalaris Therapeutics, Inc. ALVR · Entity 6805 | GrantCommon Stock | 157,500 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-006995 · doc4.xml · nonDerivative · entry 1 Sinha Vikas · CIK 0001337845 · Director · See Remarks · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,187,738 F1 · shares: The shares reported in this transaction represent Restricted Stock Units ("RSUs") issued under the AlloVir, Inc. 2020 Stock Option and Grant Plan (the "Plan"). Each RSU represents the contingent right to receive one share of the Issuer's Common Stock. 25% of the RSUs shall vest on February 2, 2024, with the remainder vesting in twelve equal quarterly installments thereafter. Read SEC document |
| January 20, 2023 Filed Jan 24, 2023 00:00 UTC | Kalaris Therapeutics, Inc. ALVR · Entity 6805 | SaleCommon Stock | 1,426 | $5.14 | $7,335.06 |
DisclosureSEC source: 0001209191-23-004502 · doc4.xml · nonDerivative · entry 2 Sinha Vikas · CIK 0001337845 · Director · See Remarks · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,030,238 F1 · kind: Represents shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units. These sales were automatic and intended to qualify under Rule 10b5-1. F3 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $5.05 to $5.22. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request. Read SEC document |
| January 19, 2023 Filed Jan 24, 2023 00:00 UTC | Kalaris Therapeutics, Inc. ALVR · Entity 6805 | SaleCommon Stock | 5,111 | $5.08 | $25,952.12 |
DisclosureSEC source: 0001209191-23-004502 · doc4.xml · nonDerivative · entry 1 Sinha Vikas · CIK 0001337845 · Director · See Remarks · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,031,664 F1 · kind: Represents shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units. These sales were automatic and intended to qualify under Rule 10b5-1. F2 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $4.94 to $5.19. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request. Read SEC document |
| October 20, 2022 Filed Oct 26, 2022 20:15 UTC Amendment | Kalaris Therapeutics, Inc. ALVR · Entity 6805 | SaleCommon Stock | 1,449 | $9.36 | $13,563.65 |
DisclosureSEC source: 0000899243-22-034261 · doc4a.xml · nonDerivative · entry 1 Sinha Vikas · CIK 0001337845 · Director · See Remarks · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,036,775 F1 · kind: Represents shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units, and does not represent a discretionary trade by the Reporting Person. F2 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $9.08 to $9.72. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request. Read SEC document |
| October 19, 2022 Filed Oct 24, 2022 22:28 UTC | Kalaris Therapeutics, Inc. ALVR · Entity 6805 | SaleCommon Stock | 1,449 | $9.36 | $13,563.65 |
DisclosureSEC source: 0000899243-22-034060 · doc4.xml · nonDerivative · entry 1 Sinha Vikas · CIK 0001337845 · Director · See Remarks · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,036,775 F1 · kind: Represents shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units, and does not represent a discretionary trade by the Reporting Person. F2 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $9.08 to $9.72. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request. Read SEC document |
| August 16, 2022 Filed Aug 17, 2022 22:04 UTC | Kalaris Therapeutics, Inc. ALVR · Entity 6805 | GrantCommon Stock | 100,000 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-22-029061 · doc4.xml · nonDerivative · entry 1 Sinha Vikas · CIK 0001337845 · Director · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,038,224 F1 · shares: The shares reported in this transaction represent restricted stock units ("RSUs") issued under the AlloVir, Inc. 2020 Stock Option and Grant Plan (the "Plan"). Each RSU represents the contingent right to receive one share of the Issuer's Common Stock. 25% of the RSUs shall vest on August 16, 2023, with the remainder vesting in twelve equal quarterly installments thereafter. Read SEC document |
| July 28, 2022 Filed Aug 1, 2022 20:38 UTC | Kalaris Therapeutics, Inc. ALVR · Entity 6805 | GrantCommon Stock | 3,253,796 | $4.61 | $14,999,999.56 |
DisclosureSEC source: 0000899243-22-027175 · doc4.xml · nonDerivative · entry 1 Sinha Vikas · CIK 0001337845 · Director · See Remarks · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · By ElevateBio LLC Disclosed balance after: 16,674,766 F1 · kind: On July 28, 2022, ElevateBio LLC ("ElevateBio") acquired 3,253,796 shares of the Issuer's Common Stock in a registered direct offering for a purchase price of $4.61 per share. F2 · ownership.nature: Shares held by ElevateBio. The Reporting Person is a director and Chief Financial Officer of ElevateBio, and may be deemed to have shared voting and investment power of the shares held by ElevateBio. The Reporting Person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose. Read SEC document |
| July 20, 2022 Filed Jul 21, 2022 23:12 UTC | Kalaris Therapeutics, Inc. ALVR · Entity 6805 | SaleCommon Stock | 1,432 | $5.21 | $7,467.16 |
DisclosureSEC source: 0000899243-22-026518 · doc4.xml · nonDerivative · entry 1 Sinha Vikas · CIK 0001337845 · Director · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 938,224 F1 · kind: Represents shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units, and does not represent a discretionary trade by the Reporting Person. F2 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $5.15 to $5.29. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request. Read SEC document |
| July 01, 2022 Filed Jul 6, 2022 11:30 UTC | Kalaris Therapeutics, Inc. ALVR · Entity 6805 | GrantStock Option (Right to Buy) · Derivative | 54,600 | $0.00 Strike: $4.13 | $0.00 |
DisclosureSEC source: 0000899243-22-025234 · doc4.xml · derivative · entry 3 Sinha Vikas · CIK 0001337845 · Director · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 54,600 Underlying: Common Stock · 54,600 shares Expires 2032-07-01 F4 · derivative.exercise_date: 25% of this option shall vest and become exercisable on July 1, 2023, with the remainder vesting in twelve equal quarterly installments thereafter. Read SEC document |
| July 01, 2022 Filed Jul 6, 2022 11:30 UTC | Kalaris Therapeutics, Inc. ALVR · Entity 6805 | GrantCommon Stock | 29,400 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-22-025234 · doc4.xml · nonDerivative · entry 1 Sinha Vikas · CIK 0001337845 · Director · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 939,656 F1 · shares: The shares reported in this transaction represent Restricted Stock Units ("RSUs") issued under the AlloVir, Inc. 2020 Stock Option and Grant Plan (the "Plan"). Each RSU represents the contingent right to receive one share of the Issuer's Common Stock. 25% of the RSUs shall vest on July 1, 2023, with the remainder vesting in twelve equal quarterly installments thereafter. F2 · balance_after: Includes 3,623 shares acquired under the AlloVir, Inc. 2020 Employee Stock Purchase Plan on June 30, 2022. Read SEC document |
| April 28, 2022 Filed Apr 29, 2022 20:48 UTC | Verona Pharma plc VRNA · Entity 74409 | GrantShare Options (Right to Buy) · Derivative | 200,000 | $0.00 Strike: $0.50 | $0.00 |
DisclosureSEC source: 0001104659-22-053720 · tm2214046-5_4seq1.xml · derivative · entry 1 Sinha Vikas · CIK 0001337845 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 200,000 Underlying: Ordinary Shares · 200,000 shares Expires 2032-04-27 F1 · derivative.exercise_price: The number of securities underlying the option and the exercise price therefor are listed in terms of Ordinary Shares, however, each security is represented by American Depositary Shares ("ADSs"), each of which represents eight (8) Ordinary Shares of the Issuer. F1 · shares: The number of securities underlying the option and the exercise price therefor are listed in terms of Ordinary Shares, however, each security is represented by American Depositary Shares ("ADSs"), each of which represents eight (8) Ordinary Shares of the Issuer. F2 · derivative.exercise_date: The option vests and becomes exercisable as to 25% on each of July 28, 2022, October 28, 2022, January 28, 2023 and April 28, 2023. F1 · derivative.underlying_shares: The number of securities underlying the option and the exercise price therefor are listed in terms of Ordinary Shares, however, each security is represented by American Depositary Shares ("ADSs"), each of which represents eight (8) Ordinary Shares of the Issuer. F1 · balance_after: The number of securities underlying the option and the exercise price therefor are listed in terms of Ordinary Shares, however, each security is represented by American Depositary Shares ("ADSs"), each of which represents eight (8) Ordinary Shares of the Issuer. Read SEC document |
| April 20, 2022 Filed Apr 22, 2022 12:29 UTC | Kalaris Therapeutics, Inc. ALVR · Entity 6805 | SaleCommon Stock | 1,162 | $6.68 | $7,767.16 |
DisclosureSEC source: 0000899243-22-015394 · doc4.xml · nonDerivative · entry 1 Sinha Vikas · CIK 0001337845 · Director · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 906,633 F1 · kind: Represents shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units, and does not represent a discretionary trade by the Reporting Person. F2 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $6.665 to $6.6976. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request. Read SEC document |
| January 20, 2022 Filed Jan 24, 2022 21:15 UTC | Kalaris Therapeutics, Inc. ALVR · Entity 6805 | SaleCommon Stock | 6,450 | $8.75 | $56,454.27 |
DisclosureSEC source: 0000899243-22-003002 · doc4.xml · nonDerivative · entry 1 Sinha Vikas · CIK 0001337845 · Director · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 858,957 F1 · kind: Represents shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of restricted stock, and does not represent a discretionary trade by the reporting person. F2 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $8.49 to $9.09. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request. Read SEC document |
| January 18, 2022 Filed Apr 4, 2022 20:25 UTC | Kalaris Therapeutics, Inc. ALVR · Entity 6805 | GrantStock Option (Right to Buy) · Derivative | 119,162 | $0.00 Strike: $9.15 | $0.00 |
DisclosureSEC source: 0000899243-22-013338 · doc4.xml · derivative · entry 3 Sinha Vikas · CIK 0001337845 · Director · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 119,162 Underlying: Common Stock · 119,162 shares Expires 2032-01-18 F3 · derivative.exercise_date: 25% of this option shall vest and become exercisable on January 18, 2023, with the remainder vesting in twelve equal quarterly installments thereafter. Read SEC document |
| January 18, 2022 Filed Apr 4, 2022 20:25 UTC | Kalaris Therapeutics, Inc. ALVR · Entity 6805 | GrantCommon Stock | 48,838 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-22-013338 · doc4.xml · nonDerivative · entry 1 Sinha Vikas · CIK 0001337845 · Director · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 907,795 F1 · shares: The shares reported in this transaction represent Restricted Stock Units ("RSUs") issued under the AlloVir, Inc. 2020 Stock Option and Grant Plan (the "Plan"). Each RSU represents the contingent right to receive one share of the Issuer's Common Stock. 25% of the RSUs shall vest on January 18, 2023, with the remainder vesting in twelve equal quarterly installments thereafter. Read SEC document |
| August 09, 2021 Filed Aug 10, 2021 20:47 UTC | Verona Pharma plc VRNA · Entity 74409 | GrantShare Options (Right to Buy) · Derivative | 64,000 | $0.00 Strike: $0.78 | $0.00 |
DisclosureSEC source: 0001104659-21-102898 · tm2124631-9_4seq1.xml · derivative · entry 1 Sinha Vikas · CIK 0001337845 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 64,000 Underlying: Ordinary Shares · 64,000 shares Expires 2031-08-08 F1 · derivative.exercise_price: The number of securities underlying the option and the exercise price therefor are listed in terms of Ordinary Shares, however, each security is represented by American Depositary Shares ("ADSs"), each of which represents eight (8) Ordinary Shares of the Issuer. F1 · shares: The number of securities underlying the option and the exercise price therefor are listed in terms of Ordinary Shares, however, each security is represented by American Depositary Shares ("ADSs"), each of which represents eight (8) Ordinary Shares of the Issuer. F2 · derivative.exercise_date: The option vests and becomes exercisable as to 25% on August 9, 2021, 25% on November 1, 2021, 25% on February 1, 2022 and 25% on May 1, 2022. F1 · derivative.underlying_shares: The number of securities underlying the option and the exercise price therefor are listed in terms of Ordinary Shares, however, each security is represented by American Depositary Shares ("ADSs"), each of which represents eight (8) Ordinary Shares of the Issuer. F1 · balance_after: The number of securities underlying the option and the exercise price therefor are listed in terms of Ordinary Shares, however, each security is represented by American Depositary Shares ("ADSs"), each of which represents eight (8) Ordinary Shares of the Issuer. Read SEC document |
| May 04, 2021 Filed May 5, 2021 21:05 UTC | Verona Pharma plc VRNA · Entity 74409 | SaleOrdinary Shares | 10,016 | $0.84 | $8,410.44 |
DisclosureSEC source: 0001104659-21-061808 · tm2115267-6_4seq1.xml · nonDerivative · entry 1 Sinha Vikas · CIK 0001337845 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 74,440 F1 · security: Reported securities are represented by American Depositary Shares ("ADSs"), each of which represents eight (8) Ordinary Shares of the Issuer. F2 · kind: The sale reported in the Form 4 was effected pursuant to a Rule 10b5-1 instruction solely with the intent to cover withholding taxes in connection with the settlement of Restricted Stock Units. F3 · price: The price reported is a weighted average price, and is based on the sale price of the ADSs divided by eight (8). The securities were sold in multiple transactions at per share prices ranging from $0.8063 to $0.8525. The Reporting Person undertakes to provide upon request to the SEC staff, the Issuer, or any shareholder of the Issuer, full information regarding the number of securities sold at each separate price within the range set forth in this footnote 3. F4 · balance_after: Consists of 74,440 Ordinary Shares represented by 9,305 ADSs. Read SEC document |
| February 01, 2021 Filed Feb 4, 2021 00:11 UTC | Verona Pharma plc VRNA · Entity 74409 | SaleOrdinary Shares | 10,224 | $0.99 | $10,160.61 |
DisclosureSEC source: 0001104659-21-011748 · tm215272-5_4seq1.xml · nonDerivative · entry 1 Sinha Vikas · CIK 0001337845 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 84,456 F1 · security: Reported securities are represented by American Depositary Shares ("ADSs"), each of which represents eight (8) Ordinary Shares of the Issuer. F2 · kind: The sale reported in the Form 4 was effected pursuant to a Rule 10b5-1 instruction solely with the intent to cover withholding taxes in connection with the settlement of Restricted Stock Units. F3 · price: The price reported is a weighted average price, and is based on the sale price of the ADSs divided by eight (8). The securities were sold in multiple transactions at per share prices ranging from $0.99375 to $0.99625. The Reporting Person undertakes to provide upon request to the SEC staff, the Issuer, or any shareholder of the Issuer, full information regarding the number of securities sold at each separate price within the range set forth in this footnote 3. F4 · balance_after: Consists of (i) 29,000 Ordinary Shares underlying Restricted Share Units, each of which represents a contingent right to receive one (1) Ordinary Share of the Issuer (which are represented by 3,625 ADSs); and (ii) 55,456 Ordinary Shares represented by 6,932 ADSs. Read SEC document |
| January 19, 2021 Filed Jan 22, 2021 00:27 UTC | Kalaris Therapeutics, Inc. ALVR · Entity 6805 | GrantStock Option (Right to Buy) · Derivative | 109,200 | $0.00 Strike: $42.15 | $0.00 |
DisclosureSEC source: 0000899243-21-002765 · doc4.xml · derivative · entry 3 Sinha Vikas · CIK 0001337845 · Director · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 109,200 Underlying: Common Stock · 109,200 shares Expires 2031-01-19 F3 · derivative.exercise_date: 25% of this option shall vest and become exercisable on January 19, 2022, with the remainder vesting in twelve equal quarterly installments thereafter. Read SEC document |
| January 19, 2021 Filed Jan 22, 2021 00:27 UTC | Kalaris Therapeutics, Inc. ALVR · Entity 6805 | GrantCommon Stock | 58,800 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-21-002765 · doc4.xml · nonDerivative · entry 1 Sinha Vikas · CIK 0001337845 · Director · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 865,407 F1 · shares: The shares reported in this transaction represent Restricted Stock Units ("RSUs") issued under the AlloVir, Inc. 2020 Stock Option and Grant Plan (the "Plan"). Each RSU represents the contingent right to receive one share of the Issuer's Common Stock. 25% of the RSUs shall vest on January 19, 2022, with the remainder vesting in twelve equal quarterly installments thereafter. Read SEC document |
| August 03, 2020 Filed Aug 6, 2020 01:57 UTC | Kalaris Therapeutics, Inc. ALVR · Entity 6805 | ConversionSeries A-2 Convertible Preferred Stock · Derivative | 20,000,000 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000899243-20-021588 · doc4.xml · derivative · entry 3 Sinha Vikas · CIK 0001337845 · Director · See Remarks · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 0 Underlying: Common Stock · 13,420,970 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each share of convertible preferred stock automatically converted into the Issuer's Common Stock on a one-for-1.49021 basis upon the closing of the Issuer's initial public offering on August 3, 2020 and had no expiration date. F1 · price: Each share of convertible preferred stock automatically converted into the Issuer's Common Stock on a one-for-1.49021 basis upon the closing of the Issuer's initial public offering on August 3, 2020 and had no expiration date. F1 · derivative.exercise_date: Each share of convertible preferred stock automatically converted into the Issuer's Common Stock on a one-for-1.49021 basis upon the closing of the Issuer's initial public offering on August 3, 2020 and had no expiration date. F1 · derivative.expiration_date: Each share of convertible preferred stock automatically converted into the Issuer's Common Stock on a one-for-1.49021 basis upon the closing of the Issuer's initial public offering on August 3, 2020 and had no expiration date. F2 · ownership.nature: Shares held by ElevateBio LLC ("ElevateBio"). The Reporting Person is a director and Chief Financial Officer of ElevateBio, and may be deemed to have shared voting and investment power of the shares held by ElevateBio. The Reporting Person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose. Read SEC document |
| August 03, 2020 Filed Aug 6, 2020 01:57 UTC | Kalaris Therapeutics, Inc. ALVR · Entity 6805 | ConversionCommon Stock | 13,420,970 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000899243-20-021588 · doc4.xml · nonDerivative · entry 1 Sinha Vikas · CIK 0001337845 · Director · See Remarks · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 13,420,970 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each share of convertible preferred stock automatically converted into the Issuer's Common Stock on a one-for-1.49021 basis upon the closing of the Issuer's initial public offering on August 3, 2020 and had no expiration date. F2 · ownership.nature: Shares held by ElevateBio LLC ("ElevateBio"). The Reporting Person is a director and Chief Financial Officer of ElevateBio, and may be deemed to have shared voting and investment power of the shares held by ElevateBio. The Reporting Person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose. Read SEC document |
| July 29, 2020 Filed Jul 31, 2020 22:40 UTC | Kalaris Therapeutics, Inc. ALVR · Entity 6805 | GrantStock Option (Right to Buy) · Derivative | 436,900 | $0.00 Strike: $17.00 | $0.00 |
DisclosureSEC source: 0000899243-20-020925 · doc4.xml · derivative · entry 1 Sinha Vikas · CIK 0001337845 · Director · See Remarks · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 436,900 Underlying: Common Stock · 436,900 shares Expires 2030-07-29 F1 · derivative.exercise_date: 25% of this option shall vest and become exercisable on July 29, 2021, with the remainder vesting in twelve equal quarterly installments thereafter. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.